Marc Vooijs |
 |
|
Dr. Marc Vooijs no longer works in the UMC Utrecht, but in Maastricht University since September 2010. As an external supervisor, however, he co supervises several PhD Students, who started during his UMC Utrecht period, till they have graduated. |
| Name: |
Marc A.G.G. Vooijs, PhD |
| Present Position: |
Senior Scientist
External duo groupleader
Since September 2010
Maastricht University
GROW School for Oncology and Developmental Biology |
| E-mail address: |
marc.vooijs@maastrichtuniversity.nl |
| Phone number: |
+ 31 (0)43 388 2912 |
| Fax number: |
+ 31 (0)43 388 4540 |
| Visiting address: |
Universiteitssingel 50
6229 ER Maastricht
The Netherlands |
|
Marc Vooijs studied Biology at the University of Nijmegen. During his PhD, he developed conditional mouse models for sporadic cancer in the group of Anton Berns at the Netherlands Cancer Institute. Using Cre-LoxP and Flp-FRT site specifc recombinase systems he generated conditional alleles of the Retinoblastoma tumor suppressor genes and studied the effect of RB loss in several tissues including the retina. In these tumor models he also expressed firefly luciferase and used Bioluminescence imaging to monitor the growth and response to anticancer agents in living mice. He received his PhD in 2001. As a postdoc he worked with Raphael Kopan at the Washington University in Saint Louis on Notch signaling as a fellow of the Dutch Cancer Society. Here he developed a mouse model to follow the fate of cells experiencing Notch1 activation and studied proteases involved in Notch activation. In 2004 he continued this work in the laboratory of Hans Clevers at the Hubrecht Institute studying the role of Notch activating in colorectal cancer. In 2006 he joined the Pathology department as a group leader. In 2008 he received an ERC Young Investigator Grant. His group is focussed on dissecting the proteolytic machinery activating Notch and building preclinical mouse models to block Notch activity in cancer. His group together with Paul van Diest and Elsken van der Wall also works on hypoxia and HIF signaling breast cancer.
|